Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis.
- Author:
Qi SONG
;
Xiaoming LI
;
Bin LI
;
Bin DI
;
Shufen XIAO
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Carcinoma, Squamous Cell;
drug therapy;
Disease-Free Survival;
ErbB Receptors;
immunology;
Head and Neck Neoplasms;
drug therapy;
Humans;
Randomized Controlled Trials as Topic;
Squamous Cell Carcinoma of Head and Neck
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2015;29(9):815-821
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To perform a Meta-analysis of all randomized controlled trials that compared the efficacy and adverse events profile of Mabs for LA HNSCC.
METHOD:Several databases were searched, including CBM, PUBMED, EMBASE, and CENTRAL. Primary outcomes included overall response rate (ORR), overall survival (OS), progression-free survival (PFS). Secondary outcomes included serious adverse events, such as grade 3-4 skin reaction, dysphagia, mucositis, and nausea/vomiting. The results were expressed as relative ratio (RR) or hazard rate (HR) with their corresponding 95% CI.
RESULT:The final analysis included 10 trials. The primary analyses indicated that Mabs did not improve ORR and PFS, except OS for locoregionally advanced (LA) HNSCC [ORR 1.21, 95% CI (0.97 - 1.49); PFS 0.87, 95% CI (0.75 - 1.01); OS 0.82, 95% CI (0.71 - 0.95)]. Analysis of adverse effects demonstrated that grade 3 - 4 skin reaction ERR 1.87, 95% CI (1.11 - 3.16)] was statistically significantly associated with Mabs except dysphagia ERR 0. 95, 95% CI (0.75 - 1.19)], Mucositis ERR 1.03, 95% CI (0.67 - 1.57)], and nausea/vomiting ERR 1.15, 95% CI (0.71 - 1.86)].
CONCLUSION:Anti-EGFR Mabs may be satisfactory for improving OS of LA HNSCC. During the Mabs therapy, skin reaction should be much more monitored.
